Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OMNI-Lab Smoothing the Way to Expanded Newborn Screening at GSTS Pathology

Published: Monday, September 09, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
Laboratory management software ensure that babies are not only screened within days of birth for the five established life-threatening diseases of infancy, but also for a further five rare conditions.

Integrated Software Solutions Ltd has announced the latest implementation of its OMNI-Lab Newborn Screening management suite, this time at GSTS Pathology LLP, the unique and innovative joint venture between Guy’s and St Thomas’ and King’s College Hospital NHS Foundation Trusts and Serco plc.

OMNI-Lab software is at the heart of a system that facilitates the safe and efficient management of bloodspots, taken by heel prick for screening from thousands of newborn infants each year in the South East Thames region (approx. 60,000 live births p.a.).

The screening either indicates that the infants are not suspected of having any of five serious diseases of infancy, or alerts paediatricians to the need for further testing and/or possible treatment.

Prior to implementing OMNI-Lab, GSTS had been using a bespoke LIMS based on a custom-written and since unsupported Microsoft™ Access 97™ database.

Staff were concerned that the database was at increasing risk of data loss or corruption - unthinkable given the critically-important nature of the data being acquired and stored.

In addition, the system was rapidly becoming obsolete in the face of new standards and was unable to interface with various laboratory analyzers. So tenders were invited from several providers and Integrated Software Solutions, the developer of OMNI-Lab, was selected.

Analie Booth, Service Delivery Manager – Biochemical Sciences at the time, stated: “We chose OMNI-Lab for its good electronic links, the fact that it future-proofed us and we liked its flexibility.”

Unlike previous customers for OMNI-Lab, who have usually opted for an off-the-peg solution, GSTS decided to get right under the skin of the system and build their own version from scratch. That meant several people learning how to write SQL and first they had to be trained by ISS.

Analie explains: “We’ve got a system now that’s bespoke for us, but which is fully supported by ISS. We’ve built up the capability in house such that we’ve got experts on site and don’t have to wait for ISS to come up with the solutions to problems for us - we can start working on them ourselves, which is a massive bonus. Having said that, we’ve had a lot of support from the ISS guys both in Winchester, here in the UK and in Australia and that’s ongoing.”

She added: “Although the implementation hasn’t been without teething problems, we’re getting there and we feel an awful lot safer than we did previously. We’ve also got interfaces to all our analyzers, something we didn’t have before. In phase two of the project we’re looking to introduce messaging with child health and maternity units through an N3 secure data connection, allowing us to download patient details and populate our database automatically.”

GSTS is currently taking part in a pilot study for expanded newborn screening, so in addition to the usual five tests they are also screening for five additional but rare conditions: Glutaric Aciduria Type 1 (GA1), Homocystinuria [pyridoxine unresponsive] (HCU), Isovaleric Acidemia (IVA), Maple Syrup Urine Disease (MSUD) and Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD.

Analie comments: “As this is a pilot project we are not required to report the results of the extra tests back to the Child Health Records Department. At the moment we simply record the results and suppress them so they are not sent out to clinicians, but are available internally for statistical analysis.”

Analie observes that GSTS is constantly reviewing processes and that includes what is happening with OMNI-Lab so that, before manual checks are removed, the system is as safe as it possibly can be.

She concludes: “OMNI-Lab has made us a lot safer overall and we have much more confidence in what’s happening with our processes. Phase two of the project will set the seal on OMNI-Lab’s effectiveness for us.”

Project Manager David Doran signed off for GSTS: “GSTS and Integrated Software Solutions (ISS) recently worked together to replace our existing newborn screening lab IT system with OMNI-Lab’s. The ISS Project Manager joined us in regular team meetings which brought about a very cohesive approach to meeting deadlines and making sure resources were available. We found ISS to have a ‘can-do’ approach to our project and they were very supportive in getting the job done. Completing this project as ‘one team’ ensured the project was delivered on time and under budget and will be an exemplar for our future projects.”

Alex Anderson, Managing Director of Integrated Software Solutions, noted: “What GSTS has done with OMNI-Lab illustrates perfectly just how versatile and therefore powerful it is – whether a lab wants to take an off-the-shelf solution straight from us or customize the suite to a high degree. It’s particularly exciting for us to be helping GSTS play its part in the Expanded Newborn Screening study, which is surely another ringing endorsement for OMNI-Lab in itself.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!